Company expands into key market verticals in diagnostics, therapeutics, and research discovery with solutions for proteins, genomics, and diagnostic assay development services.
Waltham, MA – Fortis Life Sciences, a strategic platform company providing capital, expertise, and operational resources to grow founder-led life science companies, today announced highlights from its first year of operations. Fortis delivered strong financial performance in 2021 and has significantly scaled its commercial capabilities. Over the course of the last thirteen months, the company has built a portfolio of high-quality products and brands serving attractive end markets including diagnostic, therapeutic and discovery, through its acquisition of four complementary companies:
“We’re incredibly fortunate to have these companies integrated into the Fortis organization,” said Brian Kim, Chief Executive Officer of Fortis Life Sciences. “Each brings a loyal customer base born from a reputation for exceptional products and services. As part of the Fortis platform, each will benefit from ongoing ...
